|
140 documents found matching dt:article.
|
|
of 14
Prev
Next
|
|
|
|
Showing 1-10 of 140 documents
|
1.
Konstam MA et al Cardiovascular thrombotic events in controlled, clinical trials of rofcoxib Circulation 2001 Nov; 104(19); 2280-8
|
Document Date:
|
20011101
|
|
Search Terms in Context:
|
to Merck and Co and Pharmacia, and Dr Konstam also has been a paid consultant to Pfizer Inc. Neither has been compensated for work on this article. Drs Reicin, Shapiro, Sperling, Barr, and Gertz are employees of Merck Research Laboratories, Merck and Co, Inc. As such, they receive financial compensation that includes stock ownership and stock options.
This article originally appeared Online on October
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17l10
|
|
| |
2.
K. Green et al Pronounced Reduction of in vivo Prostacyclin Synthesis in Humans by Acetaminophen Prostaglandins, Mar. 1989, vol. 37:311-315
|
Document Date:
|
19890301
|
|
Author:
|
Green, K
|
|
Search Terms in Context:
|
*
* *
PROSTAGLANDINS
*< ,?.*t
• :w
numeric» or ar vrvo
BT JCRMUJHJW (YJÜUtCRHttZO
Great»,, v. Drvota» and O. veetesqwiet
___** Clinical Chaaiatrr and Blood Coagulation
Vaseline*» scapitai, B-104 01 Stockholm, ^^
BBISSaCf.
ri
+
tba affact of a aiuola doaa of 500 «9 acetaminophen {pttracetanol) on the in vivo synthesis of prostacyclin va* studied In healthy volimtaara by neaaureaents of tba urinary axeratio» of 2,3-dinor-6~*eto-FOFlft, ¿cet- ¦ enlnophen fines* » ^»**»4 *~*-*-fi»n of proetacvSEfiT j
inane eynthssla. Thus, acetaminophen nay at least theoretically be ólaadvantagsous for patianta auf faring from diaaaaaa vhara prostacyclin aadiatad vaacular dafanco aechanlsae ara activated, like nyooerdlal infarction, daap vain throaboaia and following surgery«
wt
Hon-ataroldal antl-lnflasMatory drugs (MtAIDs) bava
antl-inxlamvstory, analgesic and antipyretic actions and «oat BSAIDe «loo affaot platelet function (1). However, la contrast to NSAID» acetaminophen, a vidaly osad anal
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx16z10
|
|
| |
3.
Economic evaluation of rofecoxib vs. non-selective . . .
|
Document Date:
|
20000504
|
|
Search Terms in Context:
|
of osteoarthritis.
Confidential - Subject To Protective Order
MRK-ABWÛ016539
pgNbr=16
Pellissier et al. 17
ACKNOWLEDGMENTS
The'authors thank Alan Morrison, Ph.D. for assisting in the preparation of this article.
Confidential - Subject To Protective Order MRK-ABW0016540
pgNbr=17
Pellissier et
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx06g10
|
|
| |
4.
Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis
|
Document Date:
|
20001123
|
|
Search Terms in Context:
|
The New England Journal of Medicine
COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
Claire Bombardier, M.D., Loren Laine, M.D., Ause Reicin, M.D., Deborah Shapiro, Dr.P.H.,
Ruben Burgos-Vargas, M.D., Barry Davis, M.D., Ph.D., Richard Day, M.D., Marcos Bosi Ferraz, M.D., Ph.D.,
Christopher J. Hawkey, M.D., Marc C. Hochberg, M.D., Tore K. Kvien, M.D.,
and Thomas J. Schnitzer, M.D., Ph.D., for the VIGOR Study Group
Abstract
Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis.
Methods We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx08j10
|
|
| |
5.
Catella-Lawson, et al: Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics and Vasoactive Eicosanoids
|
Document Date:
|
19990101
|
|
Author:
|
Catella-Lawson
|
|
Search Terms in Context:
|
1
Reference 82
Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J Pharmacol Exp Thcr
1999;289(2):735-41.
MRK-00420019123
pgNbr=1
MK-0966, Reference 82
2
0G22-35S5O9/2892-0735$03.G0/0
The Journal of Phakmacglogy amd Experimental Therapeutics
Copyright© 1999 by The American Society for Pharmacology and Expérimental Therapeutics
JPET 289:735-741, 1999
Voi, 269, No. 2 Printed in U,S,A
^l»****«i«H*i*H*ata(ta^li***ta*«^*(i^^»t*"»*l
^*t*t***+***++*********+*t0È+*Ê^^++*Ê+È^^i**mm*#*mm*m*mmmmmmmmi*^*r*+mtr*
nmiivnwHRPnnmHtnMiiiPvwtnMPnpwim
Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids1
FRANCESCA CATELLA-LAWSON,2 BRENDAN MCADAM,2'3 BRIGGS W. MORRISON, SHIV KAPOOR, DEAN KUJUBU, LISA ANTES, KENNETH C. LASSETER, HUI QUAN, BARRY J. GERTZ, and GARRET A. RTZGERALD
The EUPenn Group of investigators at the Center for Experimental Therap
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17a10
|
|
| |
6.
Risk of CV Events Associated with Cox-2 (Topol et.al.) WITH INDEX
|
Document Date:
|
20010822
|
|
Search Terms in Context:
|
JAMA
The Journal of the American Medical Association
August 22/29, 2001
pgNbr=1
terment of the Public Hi
JAMA
The Journal ot the American Medical Association
¦jiuii»n>i:]ffS!iia
ORIGINAL CONTRIBUTIONS
G A Couiir/.. M J. Stampffr. C. S Fixhs
Use of Nonprescription Weight Loss Products:
Results From a Multistate Survey........................................................................930
H. M. BlaNCK. L K. Khan. M K. SCbduLa
Cost-effectiveness of Vitamin Therapy
to Lower Plasma Homocysteine Levels
for the Prevention of Coronary Heart Disease:
Effect of Grain Fortification and Beyond ..........................................................936
CARING FOR THE CRITICALLY ILL PATIENT
Should Immunonutrition Become Routine in Critically III Patients?
A Systematic Review of the Evidence.............
d k heyunq. f. NOVAK,j. w. DlWVER. M.Jain, K.Su. U SuaiNEft
Smoking Among Japanese Physicians
SPECIAL COMMUNICATION
Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors....
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17i10
|
|
| |
7.
Patrono, Carlo et al Platelet-Active Drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest Supplement 2004; 126; 234-264
|
Document Date:
|
20040901
|
|
Author:
|
Patrono, Carlo
|
|
Search Terms in Context:
|
Platelet-Active Drugs: The
Relationships Among Dose, Effectiveness, and Side Effects
The Seventh ACCP Conference on
Antithrombotic and Thrombolytic Therapy
Barry CoBer, MD; MDiJaek Jfir*n> MD, FCCP- rmd
Cario Patrono, Carnet A Gerald Both, MD
lids article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17b10
|
|
| |
8.
Low-dose Gabapentin in the treatment of painful diabetic neuropathy:A placebo-controlled, double-blind, crossover trial
|
Document Date:
|
00000000
|
|
Author:
|
Gorson, Kenneth|Schott, Cecilia|Rand, William|Herman, Robert|Ropper, Allan
|
|
Corporate Author:
|
St. Elizabeth's Medical Center|Tufts University School of Medicine
|
|
Search Terms in Context:
|
08-25-1997 07:57AM FRGM NEUROLOGY TO 912013165007 P.02
Low-Dose Gabapentin In The Treatment Of Painful Diabeti* Neuropathy: A Placebo-Controlled, Double-Blind, Crossover Trial
Kenneth C. Gorson, M.D.
Cecelia Schott, RPh. WmiainM.lUiMl.PhD.
Robert Herman, B.S. Alian B. Ropper, BID.
Neurology Service, St. Elizabeth's Medical Center. Tufts University School of Mediriiic, Boston, MA
AdDMmsadgments: This study was financially supported by an unrestricted educational grant fiom Warner Lambert Co. (Parke-Davis Pharmaceuticals), Parke-Davis supplied gabapentin fior the purposes of this study. We would like to dunk Gregory Allan and Margot Geoflrey for their assistances data collection. keywords: neuropathy, pain» gabapentin, diabetes
Send correspondence to: Kennern C. Gorson, M.D., Division of Neurology, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, Phone #: 617-789-2375; FAX #: 617-789-5177.
ÏY.06827
WLC FRANKLIN 00001
pgNbr=1
08-25-199
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx19o10
|
|
| |
9.
New Clinical Markers Predictive of Cardiovascular Disease: The Role of Inflammatory Mediators, Charles E Rackley, MD
|
Document Date:
|
00000000
|
|
Page Count:
|
37
|
|
Search Terms in Context:
|
, and fibrinogen. In addition, a large, case-control study7 among patients with premature coronary artery disease identified multiple genetic vanants of thrombospondm associated with familial premature myocardial infarction, suggesting an important new avenue of research into the etiology of coronary atherosclerosis. This article investigates the value of C-reactive protein and closely interrelated
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pnc37b10
|
|
| |
10.
The New Science of Estrogens, Ronald W. Maddox, PharmD
|
Document Date:
|
00000000
|
|
Page Count:
|
31
|
|
Search Terms in Context:
|
The New Science of Estrogens Ronald W Maddox, Pharm D
Professor and Dean
Campbell University
School of Pharmacy
Goal: This article is designed to bring pharmacists up to date regarding the pharmacology and
pharmacodynamics of estrogen. Objectives: After reading this article, pharmacists should be able to do the following:
Describe the primary indications for estrogen therapy.
Discuss
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/roc37b10
|
|
| |
|
Prev
Next
|
